Compare RLX Technology Inc (RLX) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
RLX Technology Inc vs Twist Bioscience Corp — how do they compare? RLX Technology Inc trades at $2.02 (market cap $2.42B), while Twist Bioscience Corp trades at $122.96 (market cap $7.72B). The key difference: Twist Bioscience Corp is far larger — about 3.2× RLX Technology Inc's market cap, and RLX Technology Inc pays a 5.05% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| RLX | TWST | |
|---|---|---|
Market Cap | $2.42B | $7.72B |
Sector | Technology | Health |
52-Week High | $2.73 | $124.88 |
52-Week Low | $1.79 | $24.16 |
Enterprise Value | $1.04B | $7.65B |
Dividend Yield | 5.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RLX Technology trades at $2.02, up 1.0% with bearish technical signals despite recent earnings misses. The company maintains strong profitability with 22.47% net margins and international expansion driving revenue growth from $3.62B to $4.4B. Cash flow trends show operational strength but negative net cash flow. Analyst coverage remains limited with a single hold rating.
RLX faces execution risks from international integration while trading at reasonable valuations (P/E 17.96). The upcoming Q2 2026 earnings on August 14 will be crucial for validating growth trajectory amid competitive and regulatory pressures in the global e-vapor market.
Twist Bioscience (TWST) trades at $125.13, up 0.2% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported Q3 2026 revenue of $118.4 million, up 23% year-over-year, beating estimates, but posted a net loss. Revenue growth is strong, yet profitability remains elusive with negative margins. Recent news highlights an upsized $300 million public offering and expanding AI drug discovery pipeline.
Outlook is mixed: robust revenue growth and analyst optimism (78.57% buy ratings) support upside, but persistent losses, cash burn, and high valuation multiples pose significant risks. The stock's proximity to resistance at $126 suggests near-term volatility. Investors should weigh growth potential against financial sustainability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
